Keros Therapeutics Inc. (KROS): Price and Financial Metrics
GET POWR RATINGS... FREE!
KROS POWR Grades
- Sentiment is the dimension where KROS ranks best; there it ranks ahead of 76.85% of US stocks.
- The strongest trend for KROS is in Sentiment, which has been heading up over the past 179 days.
- KROS's current lowest rank is in the Quality metric (where it is better than 11.3% of US stocks).
KROS Stock Summary
- KROS's went public 1.98 years ago, making it older than merely 5.22% of listed US stocks we're tracking.
- KROS's price/sales ratio is 65.78; that's higher than the P/S ratio of 96.85% of US stocks.
- As for revenue growth, note that KROS's revenue has grown 20,000% over the past 12 months; that beats the revenue growth of 99.83% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Keros Therapeutics Inc, a group of peers worth examining would be PRTA, LPCN, SNDX, KDNY, and RPTX.
- Visit KROS's SEC page to see the company's official filings. To visit the company's web site, go to www.kerostx.com.
KROS Valuation Summary
- In comparison to the median Healthcare stock, KROS's price/sales ratio is 206505.26% higher, now standing at 7851.
- KROS's price/sales ratio has moved up 7814.5 over the prior 17 months.
- Over the past 17 months, KROS's EV/EBIT ratio has gone up 15.1.
Below are key valuation metrics over time for KROS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| KROS | 2021-08-31 | 7851 | 3.3 | -14.8 | -10.3 |
| KROS | 2021-08-30 | 7949 | 3.4 | -14.9 | -10.5 |
| KROS | 2021-08-27 | 8161 | 3.5 | -15.3 | -10.9 |
| KROS | 2021-08-26 | 7687 | 3.3 | -14.4 | -10.0 |
| KROS | 2021-08-25 | 7823 | 3.3 | -14.7 | -10.3 |
| KROS | 2021-08-24 | 7746 | 3.3 | -14.6 | -10.1 |
KROS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- KROS has a Quality Grade of D, ranking ahead of 8.06% of graded US stocks.
- KROS's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows KROS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0 | 1 | 21.163 |
| 2021-06-30 | 0 | 1 | 19.894 |
| 2021-03-31 | 0 | NA | 16.656 |
| 2020-12-31 | 0 | NA | 23.971 |
KROS Price Target
For more insight on analysts targets of KROS, see our KROS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $86.25 | Average Broker Recommendation | 1.25 (Strong Buy) |
KROS Stock Price Chart Interactive Chart >
KROS Price/Volume Stats
| Current price | $35.15 | 52-week high | $68.29 |
| Prev. close | $33.42 | 52-week low | $28.50 |
| Day low | $32.67 | Volume | 214,300 |
| Day high | $35.61 | Avg. volume | 140,460 |
| 50-day MA | $52.10 | Dividend yield | N/A |
| 200-day MA | $47.90 | Market Cap | 844.83M |
Keros Therapeutics Inc. (KROS) Company Bio
Keros Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on treatments for rare muscle diseases. The company was founded in 2015 and is headquartered in Lexington, MA.
Latest KROS News From Around the Web
Below are the latest news stories about Keros Therapeutics Inc that investors may wish to consider to help them evaluate KROS as an investment opportunity.
Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceLEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the 11 th Annual SVB Leerink Global Healthcare Conference on Friday, February 18th at 9:20 am ET. |
Keros Therapeutics appoints Rovaldi as Chief Operating Officer (NASDAQ:KROS)Keros Therapeutics (KROS) has appointed Christopher Rovaldi as Keros'' Chief Operating Officer, effective as of February 1, 2022.Mr |
Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating OfficerLEXINGTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the appointment of Christopher Rovaldi as Keros' Chief Operating Officer, effective as of February 1, 2022. Mr. Rovaldi previously served as a consultant to |
Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc.. |
Insider Selling: Keros Therapeutics, Inc. (NASDAQ:KROS) Insider Sells 735 Shares of StockKeros Therapeutics, Inc. (NASDAQ:KROS) insider Jennifer Lachey sold 735 shares of the firms stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $50.00, for a total transaction of $36,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this [] |
KROS Price Returns
| 1-mo | -34.46% |
| 3-mo | -34.04% |
| 6-mo | -35.96% |
| 1-year | -35.58% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -39.92% |
| 2021 | -17.05% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...